The company in question is, Novo Nordisk A/S (NYSE:NVO) currently with a stock price of 55.5 (0.87% today). The market cap for Novo Nordisk A/S is 110998.45, and is in the sector Healthcare, and Drug Manufacturers – Other industry. The target price for Novo Nordisk A/S is 60.1. Currently Novo Nordisk A/S is trading with a P/E of 27.4, and a forward P/E of 22.37. Average volume for Novo Nordisk A/S is 1334.09 and so far today it is 277610.
Performance in the last year for Novo Nordisk A/S has been -4.35%. For EPS growth, Novo Nordisk A/S has seen a growth of 34.30%, and is looking to grow in the next year to 9.09%. More long term stats show that EPS growth has been 22.40% over the last five years and could be 12.30% for the next five years. Novo Nordisk A/S has seen sales growth quarter over quarter at 8.00%, with EPS growth quarter over quarter at -2.20%. The 20-day simple moving average is 2.05%, with the 200-day simple moving average coming to 2.62%.
Since the IPO date for Novo Nordisk A/S on the 1/4/1982, Novo Nordisk A/S has seen performance year to date to be -3.59%. With Novo Nordisk A/S trading at 55.5, the dividend yield is 1.74%, and the EPS is 2.01.
So could Novo Nordisk A/S, be undervalued? Well as said before P/E is 27.4. The PEG is 2.23, P/S is 6.75 and the P/B is at 25.12. The P/cash is 83.89, with P/free cash flow at 39.75.
Novo Nordisk A/S ability to deal with debt shows that the current ratio is 1.1, and the quick ratio is 0.8. This is with long term debt/equity at 0, and total debt/equity at 0.01.
In terms of margins, Novo Nordisk A/S has a gross margin of 84.90%, an operating margin of 43.60% and a profit margin of 31.30%.Payout ratio for Novo Nordisk A/S is 47.50%. Return on assets come to 40.40% with return on investment coming to 85.00%.
Insider ownership for Novo Nordisk A/S, is at 26.40% and institutional ownership comes to 10.20%. Outstanding shares are at 2017.42. While shares float is 1356.68. The float short is currently 0.15%, and short ratio is 1.52.